cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.15151/esrf-es-1933839755
title: Investigating cellular signaling proteins and complexes using time-resolved serial crystallography.

description: For many years members of the Laboratory of Biomolecular Research have been driving the development of synchrotron based serial crystallography including pioneering static (Nogly et al., 2015 at ESRF, Weinert et al., 2017) and time-resolved experiments (Nogly et al., 2016, Weinert et al., 2019, Skopintsev et al., 2022, Weinert et al., 2023) at SLS and SwissFEL. With the coming upgrade of the SLS and an expected shutdown of 2 years, we are submitting a BAG proposal in order to continue our research projects at the ESRF. Our interests span photoactivation and ligand un-/binding in G protein-coupled receptors, kinase activation, temperature dependence of enzyme activity and multi-domain photosensors. X-ray beam brilliance, experienced beamline staff and the variety of available sample delivery methods make the ID29 beamline an ideal place to conduct the proposed projects. Additionally, the proposed work will improve collaboration between two centers of European X-ray science.
DOI: 10.6084/m9.figshare.26023267
title: Time interval between neoadjuvant radiation therapy and surgery and overall survival of rectal cancer patients

description: <b>Aim:</b> To investigate the association of time interval between neoadjuvant RT and surgery (RS-interval) with pathological complete response (pCR) and overall survival (OS) of rectal cancer patients. <b>Methods:</b> We used the National Cancer Database and reported Odds ratios (OR) and Hazard ratios. <b>Results:</b> Patients with an RS-interval of 5–24 weeks were more likely to achieve pCR compared with ≤4 weeks. RS-interval of 13–24 weeks was associated with a reduced OS compared with ≤4 weeks only in patients who did not achieve pCR. <b>Conclusion:</b> RS-interval of 5–8, 9–12, 13–16, 17–20, or 21–24 weeks was associated with a higher likelihood of achieving pCR compared with ≤4 weeks. In patients without pCR, delaying surgery &gt;12 weeks was associated with reduced OS. The optimal time between the completion of neoadjuvant radiation therapy (RT) and surgery in patients diagnosed with locally advanced rectal cancer is controversial and there is no study that has investigated this association by the pathological completed response (pCR) status. Patients who received surgery between 5 and 8 weeks, 9 and 12 weeks, 13 and 16 weeks, 17 and 20 weeks, or 21 and 24 weeks after the completion of RT were more likely to achieve pCR compared with ≤4 weeks. Patients who achieved pCR had comparable overall survival (OS) regardless of when the surgery took place within 24 weeks after RT completion. Among patients who did not achieve pCR, OS was only similar if surgery was received between 5 and 8 or 9 and 12 weeks after RT compared with ≤4 weeks. Among patients who did not achieve pCR, Surgery between 13 and 16, 71 and 20 or 21 and 24 weeks after RT was associated with worse OS compared with ≤4 weeks.
DOI: 10.6084/m9.figshare.26023267.v1
title: Time interval between neoadjuvant radiation therapy and surgery and overall survival of rectal cancer patients

description: <b>Aim:</b> To investigate the association of time interval between neoadjuvant RT and surgery (RS-interval) with pathological complete response (pCR) and overall survival (OS) of rectal cancer patients. <b>Methods:</b> We used the National Cancer Database and reported Odds ratios (OR) and Hazard ratios. <b>Results:</b> Patients with an RS-interval of 5–24 weeks were more likely to achieve pCR compared with ≤4 weeks. RS-interval of 13–24 weeks was associated with a reduced OS compared with ≤4 weeks only in patients who did not achieve pCR. <b>Conclusion:</b> RS-interval of 5–8, 9–12, 13–16, 17–20, or 21–24 weeks was associated with a higher likelihood of achieving pCR compared with ≤4 weeks. In patients without pCR, delaying surgery &gt;12 weeks was associated with reduced OS. The optimal time between the completion of neoadjuvant radiation therapy (RT) and surgery in patients diagnosed with locally advanced rectal cancer is controversial and there is no study that has investigated this association by the pathological completed response (pCR) status. Patients who received surgery between 5 and 8 weeks, 9 and 12 weeks, 13 and 16 weeks, 17 and 20 weeks, or 21 and 24 weeks after the completion of RT were more likely to achieve pCR compared with ≤4 weeks. Patients who achieved pCR had comparable overall survival (OS) regardless of when the surgery took place within 24 weeks after RT completion. Among patients who did not achieve pCR, OS was only similar if surgery was received between 5 and 8 or 9 and 12 weeks after RT compared with ≤4 weeks. Among patients who did not achieve pCR, Surgery between 13 and 16, 71 and 20 or 21 and 24 weeks after RT was associated with worse OS compared with ≤4 weeks.
DOI: 10.15151/esrf-es-1933196615
title: Structural analysis of mycelium composite for the production of wood-based carbon materials

description: Mycelium composite has attracted significant attention in the last two decades for its functionality and sustainability. While the mycelium formation is essential to the production of the composites, the fungal growth results in the decay of the cell wall structure, which is thought to be detrimental to the composite properties. Here, we utilize the wood decay to activate the biomass as a starting material for wood-based carbon materials. We expect that the wood decay will result in more porous cell wall structures, while the mycelium growth will contribute to the increase of nitrogen in the biomass due to the deposition of chitin as the main component of fungal cell walls. To examine the effects of fungal effects on the ultrastructure of wood, we will conduct a simultaneous S/WAXS experiment of mycelium composite. The results will provide insight into the structural changes and will contribute to designing of activation process of wood by fungal growth
DOI: 10.15151/esrf-es-1933200897
title: Time-resolved SAXS studies of the RAFT dispersion polymerisation of 2-hydroxyethyl methacrylate

description: We request three days of SAXS beamtime to perform time-resolved SAXS experiments during the RAFT dispersion polymerisation of 2-hydroxyethyl methacrylate (HEMA) in non-polar media. This is the key formulation for a BP-funded PhD studentship focused on the design of next-generation thermal management fluids. We will use SAXS to monitor the kinetics of polymerisation directly and to determine the local monomer concentration within the growing nanoparticles.
DOI: 10.15151/esrf-es-1933203167
title: Determination of iron environment and redox in heterogenous obsidians

description: Obsidian, a prevalent naturally occurring glass formed through rapid cooling of rhyolitic lava, holds significance in earth and material sciences, as well as archaeology. While black obsidian is widely recognized, lesser-known variants exhibit diverse colors such as green, blue, red, brown, and silver, whith often heterogeneous mixing areas. Iron, a key component in obsidian, plays a crucial role in coloration. In black obsidian, dispersed iron nanocrystals contribute to its distinct color and rheological properties To unravel the relationships betwwen iron environment/redox and color/rheological properties, nano-XANES emerges as a crucial tool, enabling the investigation of iron speciation at the nanoscale. This approach aims to discern the precise environment, redox state of iron, and its impact on color variation in crystallized and non-crystallized areas of heterogeneous obsidians.
DOI: 10.6084/m9.figshare.27052951
title: Chemotherapy delivery in early-onset colorectal cancer is impacted by urban versus rural settings in Colorado

description: <b>Aim:</b> To assess early-onset colorectal cancer (EOCRC) trends in Colorado for differences in presentation stage, therapy, survival, geography, and financial impact. <b>Materials & methods:</b> A total of 1192 EOCRC cases in Colorado were analyzed and cross-referenced with registry data for key variables with overall survival and treatment modality. Cox proportional hazard regressions and logistic regressions were used to evaluate overall survival and chemotherapy relationships respectively. <b>Results:</b> Surgical treatment was associated with a 52% improvement in overall survival. Chemotherapy was not associated with increased survival in stage II disease. Urban patients were fivefold more likely to receive chemotherapy than patients from rural areas, and patients with certain insurance types were less likely to receive chemotherapy. <b>Conclusion:</b> Differences are emerging between EOCRC and traditional CRC, particularly in access to chemotherapy. The urban–rural chemotherapy rates point to potential disparity in access to care. Further research is needed to determine larger generalizability, and how access may be affecting care. Early-onset colorectal cancer incidence has been rising nationally and across Colorado. In an analysis of a multicenter health system, urban patients were fivefold more likely to receive chemotherapy, pointing to potential disparities in access. Early-onset colorectal cancer (EOCRC) incidence is rising while CRC incidence has been falling overall since the 1990s. Rural populations have higher incidence of CRC, prompting investigation by national groups. Financial toxicity rates are higher in both EOCRC and rural populations. A multicenter academic healthcare system in Colorado was analyzed for trends in the EOCRC population. Anonymized EHR data was linked with a central cancer registry to look for granular associations with medical care received, demographic data and survival. Surgical treatment was associated with a 59% improvement in overall survival. Chemotherapy was not associated with improved survival in stage II disease. In a dedicated analysis of trends in chemotherapy, urban patients were more than five-times more likely to receive chemotherapy than rural patients. Among stage III and IV disease, urban patients were more than three-times more likely to receive chemotherapy. The findings suggest that rurality is an independent risk factor for worse survival and non-ideal treatment in EOCRC, similar to findings in CRC more broadly. Medicare-style insurance was nearly associated with chemotherapy accessibility and was less likely among rural patients, suggesting insurance status and rurality may both be worsening financial toxicity in EOCRC patients. The study population was smaller than initially anticipated due to lack of complete staging data. Many solutions have been suggested to bridge the gap in rural medical access, however many of these solutions remain incompletely tested.
DOI: 10.6084/m9.figshare.27052951.v1
title: Chemotherapy delivery in early-onset colorectal cancer is impacted by urban versus rural settings in Colorado

description: <b>Aim:</b> To assess early-onset colorectal cancer (EOCRC) trends in Colorado for differences in presentation stage, therapy, survival, geography, and financial impact. <b>Materials & methods:</b> A total of 1192 EOCRC cases in Colorado were analyzed and cross-referenced with registry data for key variables with overall survival and treatment modality. Cox proportional hazard regressions and logistic regressions were used to evaluate overall survival and chemotherapy relationships respectively. <b>Results:</b> Surgical treatment was associated with a 52% improvement in overall survival. Chemotherapy was not associated with increased survival in stage II disease. Urban patients were fivefold more likely to receive chemotherapy than patients from rural areas, and patients with certain insurance types were less likely to receive chemotherapy. <b>Conclusion:</b> Differences are emerging between EOCRC and traditional CRC, particularly in access to chemotherapy. The urban–rural chemotherapy rates point to potential disparity in access to care. Further research is needed to determine larger generalizability, and how access may be affecting care. Early-onset colorectal cancer incidence has been rising nationally and across Colorado. In an analysis of a multicenter health system, urban patients were fivefold more likely to receive chemotherapy, pointing to potential disparities in access. Early-onset colorectal cancer (EOCRC) incidence is rising while CRC incidence has been falling overall since the 1990s. Rural populations have higher incidence of CRC, prompting investigation by national groups. Financial toxicity rates are higher in both EOCRC and rural populations. A multicenter academic healthcare system in Colorado was analyzed for trends in the EOCRC population. Anonymized EHR data was linked with a central cancer registry to look for granular associations with medical care received, demographic data and survival. Surgical treatment was associated with a 59% improvement in overall survival. Chemotherapy was not associated with improved survival in stage II disease. In a dedicated analysis of trends in chemotherapy, urban patients were more than five-times more likely to receive chemotherapy than rural patients. Among stage III and IV disease, urban patients were more than three-times more likely to receive chemotherapy. The findings suggest that rurality is an independent risk factor for worse survival and non-ideal treatment in EOCRC, similar to findings in CRC more broadly. Medicare-style insurance was nearly associated with chemotherapy accessibility and was less likely among rural patients, suggesting insurance status and rurality may both be worsening financial toxicity in EOCRC patients. The study population was smaller than initially anticipated due to lack of complete staging data. Many solutions have been suggested to bridge the gap in rural medical access, however many of these solutions remain incompletely tested.
DOI: 10.15151/esrf-es-1932625938
title: Is there a liquid-liquid transition in the AsS melt ?

description: This proposal aims at studying the liquid phase of As4S4 (realgar) in order to determine whether a first-order liquid-liquid transition (LLT) exists between a molecular and a polymeric liquid under high P-T conditions. Such examples of first-order transition in the liquid state remain scarce, and this phenomena is poorly understood. Previous experimental and theoretical studies of the AsS melt suggest that a LLT exists in this system but a firm experimental proof is lacking. Here, using the state-of-the-art facilities of ID27, we will perform the first direct experimental density measurements combined with x-ray diffraction (XRD) to establish and characterize the LLT in AsS.
DOI: 10.6084/m9.figshare.26840536
title: Investigation on the cost–effectiveness of Cetuximab in treatment of colorectal cancer: a systematic review

description: <b>Aim:</b> Assess the cost–effectiveness of cetuximab, utilized as a monotherapy and in combination with other chemotherapy agents, for the treatment of different types of metastatic colorectal cancer (mCRC). <b>Materials & methods:</b> A systematic literature review of recent studies on the cost effectiveness of cetuximab. <b>Results:</b> The review highlights cetuximab's potential to enhance progression-free survival in mCRC, though its broader clinical effectiveness is subject to ongoing debate. However, its cost–effectiveness compared with bevacizumab or standard chemotherapy regimens like FOLFIRI or FOLFOX remains contested. <b>Conclusion:</b> There are discrepancies in the perceived value of anti-EGFR agents like cetuximab concerning overall survival, quality-adjusted life years and progression-free survival vis-à-vis their costs. Subsequent research should focus on balancing these clinical advantages against the financial implications. In this article, we reviewed studies on the cost–effectiveness of using a drug called Cetuximab to treat advanced colorectal cancer. We found that some studies supported the idea that Cetuximab is cost-effective, meaning it provides good value for the money spent. However, other studies suggested that it may not be cost-effective in some cases. This shows that the cost–effectiveness of Cetuximab can vary depending on different factors. More research is needed to understand when Cetuximab is the best choice for treating colorectal cancer economically. Cetuximab demonstrates cost–effectiveness in the treatment of metastatic colorectal cancer, particularly in combination therapies. Economic evaluations of Cetuximab consider various perspectives, including healthcare system and societal viewpoints. Comparators in cost–effectiveness studies include standard of care treatments and alternative targeted therapies. Outcomes measured in economic evaluations encompass life years gained, quality-adjusted life years and direct and indirect costs. Comprehensive cost estimation methods are utilized, incorporating drug costs, healthcare utilization and adverse event expenses. Sensitivity analyzes are conducted to assess the robustness of cost–effectiveness results and account for uncertainties. Transparent reporting of methods, results and limitations in economic evaluations enhances the credibility of the findings. Discounting of costs and outcomes over time is appropriately applied in economic evaluations to reflect time preferences. The relevance of study findings to the research question and systematic review objectives is crucial for drawing meaningful conclusions. The systematic review provides a comprehensive analysis of the methodological quality and risk of bias in economic evaluations of Cetuximab in metastatic colorectal cancer, contributing valuable insights to decision-making processes.
DOI: 10.6084/m9.figshare.26840536.v1
title: Investigation on the cost–effectiveness of Cetuximab in treatment of colorectal cancer: a systematic review

description: <b>Aim:</b> Assess the cost–effectiveness of cetuximab, utilized as a monotherapy and in combination with other chemotherapy agents, for the treatment of different types of metastatic colorectal cancer (mCRC). <b>Materials & methods:</b> A systematic literature review of recent studies on the cost effectiveness of cetuximab. <b>Results:</b> The review highlights cetuximab's potential to enhance progression-free survival in mCRC, though its broader clinical effectiveness is subject to ongoing debate. However, its cost–effectiveness compared with bevacizumab or standard chemotherapy regimens like FOLFIRI or FOLFOX remains contested. <b>Conclusion:</b> There are discrepancies in the perceived value of anti-EGFR agents like cetuximab concerning overall survival, quality-adjusted life years and progression-free survival vis-à-vis their costs. Subsequent research should focus on balancing these clinical advantages against the financial implications. In this article, we reviewed studies on the cost–effectiveness of using a drug called Cetuximab to treat advanced colorectal cancer. We found that some studies supported the idea that Cetuximab is cost-effective, meaning it provides good value for the money spent. However, other studies suggested that it may not be cost-effective in some cases. This shows that the cost–effectiveness of Cetuximab can vary depending on different factors. More research is needed to understand when Cetuximab is the best choice for treating colorectal cancer economically. Cetuximab demonstrates cost–effectiveness in the treatment of metastatic colorectal cancer, particularly in combination therapies. Economic evaluations of Cetuximab consider various perspectives, including healthcare system and societal viewpoints. Comparators in cost–effectiveness studies include standard of care treatments and alternative targeted therapies. Outcomes measured in economic evaluations encompass life years gained, quality-adjusted life years and direct and indirect costs. Comprehensive cost estimation methods are utilized, incorporating drug costs, healthcare utilization and adverse event expenses. Sensitivity analyzes are conducted to assess the robustness of cost–effectiveness results and account for uncertainties. Transparent reporting of methods, results and limitations in economic evaluations enhances the credibility of the findings. Discounting of costs and outcomes over time is appropriately applied in economic evaluations to reflect time preferences. The relevance of study findings to the research question and systematic review objectives is crucial for drawing meaningful conclusions. The systematic review provides a comprehensive analysis of the methodological quality and risk of bias in economic evaluations of Cetuximab in metastatic colorectal cancer, contributing valuable insights to decision-making processes.
DOI: 10.15151/esrf-es-1942483362
title: Probing the magnetic dichroisms of emergent interfacial magnetic order in rare-earth nickelate / titanate superlattices

description: Our recent investigation of LaNiO3/LaTiO3 superlattices using resonant inelastic x-ray scattering (RIXS) and muon spin rotation (uSR) has revealed the emergence of a novel interfacial quasi-2D magnetic order. However, the microscopic details of this magnetic order, such as its type (ferromagnetic or antiferromagnetic) and orientation are still unknown. Its magnetic transition temperature of 18 K measured by uSR is also very low compared to its high magnon energy of ~100 meV measured by RIXS (corresponding to a theoretical transition temperature of &gt;1000 K). Here, we propose to do a systematic study of this LaNiO3/ LaTiO3 using x-ray magnetic linear and circular dichroism spectroscopies (XMLD and XMCD) to determine the type and orientation of its interfacial magnetic order and verify its magnetic transition temperature.
DOI: 10.15468/dl.yawzxg
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Psammechinus intermedius A.Agassiz, 1864",
 "Geometry POLYGON((170 20, 170 50, 120 50, 120 20, 170 20))",
 "HasCoordinate is true"
 ]
}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0010886-241126133413365/datasets/export for details.
DOI: 10.6084/m9.figshare.26310349
title: Tumor immune microenvironment and response of immunotherapy in patients with colorectal cancer

description: <b>Aim:</b> Biomarkers, such as PD-L1, have enabled significant progress in predicting the efficacy of immunosuppressants. However, they may not accurately predict the benefit degree from immunotherapy. Therefore, we associated PD-L1 with tumor-infiltrating lymphocytes for accurate guidance in immunotherapy. <b>Methods:</b> The expressions of diverse proteins in 68 patients with positive PD-L1 expression were detected. The response to immunotherapy and its clinical results were observed and analyzed. <b>Results:</b> The overall response rate of immunotherapy differed significantly among groups (75%; 57.58%; 10%; and 0), as did the 3-year overall survival rates (72.73%, 54.84%, 11.11%, and 0). <b>Conclusion:</b> We identified four immune subtypes of colorectal cancer with different tumor-infiltrating lymphocytes (TILs), and constructed a highly operable method for immunotyping to predict the immunotherapy efficacy. We identified four immune subtypes of colorectal cancer with different TILs, their distribution, and different immune responses and constructed a highly operable and simple method for immunotyping. Classification of immune microenvironment in colorectal cancer – four immune subtypes of colorectal cancer with different TILs and different immune responses were determined. Immune typing method – a highly operable and simple method for immunotyping was constructed. The necessity of tumor immunophenotyping – the tumor immune microenvironment is heterogeneous and patients with different immune microenvironments responded differently to PD-1 and PD-L1 inhibitors. Differences in therapeutic efficacy among different immune subtypes – the HIRG had a very good curative effect, the LIRG had a good curative effect and the IDG and IRG had poor or even ineffective curative effects. The significance of immune classification – TILs can be used as new biomarkers to predict the efficacy of immunotherapy, which is important for guiding individualized immunotherapy.